Intas Pharma has completed the acquisition of UDENYCA for $558 million, the company said in a release.
UDENYCA is a biosimilar to Neulasta or Pegfilgrastim. It is used to treat side effects of radiation therapy in cancer patients such as recurrent infections.
Intas acquired the biosimilar drug from California-based Coherus Life Sciences in December 2024.
“This acquisition cements our position as a global leader in pegfilgrastim and allows us to further expand our specialty division across key international markets,” said Binesh Chudgar, Intas Pharma’s chairman and managing director.
Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, have acquired UDENYCA.
With the acquisition, Accord BioPharma, the U.S. specialty business of Intas, continues the commercialization of UDENYCA to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia, the company's release stated.
“The completion of the UDENYCA acquisition marks a pivotal moment for Accord BioPharma, as it not only strengthens our market presence but broadens our capabilities as we endeavour to innovate and expand in the biosimilar space,” said Chrys Kokino, President, USA, Accord BioPharma.
UDENYCA is a biosimilar to Neulasta or Pegfilgrastim. It is used to treat side effects of radiation therapy in cancer patients such as recurrent infections.
Intas acquired the biosimilar drug from California-based Coherus Life Sciences in December 2024.
“This acquisition cements our position as a global leader in pegfilgrastim and allows us to further expand our specialty division across key international markets,” said Binesh Chudgar, Intas Pharma’s chairman and managing director.
Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, have acquired UDENYCA.
With the acquisition, Accord BioPharma, the U.S. specialty business of Intas, continues the commercialization of UDENYCA to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia, the company's release stated.
“The completion of the UDENYCA acquisition marks a pivotal moment for Accord BioPharma, as it not only strengthens our market presence but broadens our capabilities as we endeavour to innovate and expand in the biosimilar space,” said Chrys Kokino, President, USA, Accord BioPharma.
You may also like
UAE: Etihad hits record 20.3 million passengers in 12 months for the first time
'Ask your paw paw ...': Congress mocks BJP's Sonia Gandhi voter row; calls it 'good photoshop'
Tourists on Costa del Sol beach cheat death as out-of-control jet ski speeds at them
Max Verstappen seen on Toto Wolff's yacht in transfer twist as new photos released
Horrific CCTV Footage Captures Exact Moment When Tree Uproots And Crushes Biker Under It In Delhi's Kalkaji; 1 Killed, 2 Injured
